
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Prime Global and Raremark have announced a partnership aiming to transform solutions for patients with rare diseases.
The partnership will combine Raremark’s Xperiome platform for patients with Prime Global’s 23 years of medical communications experience aiming to uncover insights into the entire patient journey that will allow the creation of a patient-centric drug development and commercialization programs.
For more information, click






